Acute Myeloid Leukemia (AML) Clinical Trial
Official title:
A Phase 2a Open-Label Clinical Trial Evaluating Efficacy & Safety of CPI-613 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML), and in Patients With Myelodysplastic Syndrome (MDS) Who Failed Hypomethylating Agents
The purpose of this study is to determine whether CPI-613 is effective and safe in either patients with refractory or relapsed acute myeloid leukemia (AML) or patients with myelodysplastic syndrome (MDS) who have failed therapy with a hypomethylating agent (such as decitabine [Vidaza] and azacitidine [AZA]).
A new therapy for AML is necessary because, although there are several treatment options for
patients with AML, these treatments are very toxic and not available to all AML patients or
only useful for acute promyelocytic leukemia (APL). Also, there is essentially no treatment
for patients with refractory or relapsed AML outside of bone marrow transplant. Accordingly,
there is a great medical need for a safe and effective therapy for AML, especially
refractory and relapsed AML. Also, although hypomethylating agents have been found to be
effective against MDS, these agents are toxic. Furthermore, after relapsing from a
hypomethylating agent, there is no treatment for this disease.
A nearly completed clinical trial of CPI-613 (Cornerstone Study# CL-CPI-613-009 or Wake
Forest Study# CCCWFU 29109, under IND# 107,800) shows that CPI-613 is well tolerated at
doses as high as 3,000 mg/m2. Results from this nearly completed trial also suggest that
CPI- 613 may be effective against refractory and relapsed AML, as well as against MDS that
is relapsed from a hypomethylating agent. Therefore, CPI-613 may be a suitable treatment
option for refractory/relapsed AML and MDS relapsed from a hypomethylating agent. The
promising preliminary efficacy data from Study# CL-CPI-613-009 (Wake Forest Study# CCCWFU
29109, under IND# 107,800) is the basis on which Cornerstone is conducting the current Phase
2a trial to further assess the efficacy of CPI-613 against these diseases.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04240002 -
A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 1/Phase 2 | |
| Completed |
NCT02626715 -
Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS
|
Phase 2 | |
| Completed |
NCT05488613 -
Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML)
|
||
| Completed |
NCT02265731 -
Study Evaluating Venetoclax in Subjects With Hematological Malignancies
|
Phase 1/Phase 2 | |
| Terminated |
NCT02927938 -
Leukemia Stem Cell Detection in Acute Myeloid Leukemia
|
Phase 3 | |
| Completed |
NCT01772953 -
Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT
|
Phase 2 | |
| Recruiting |
NCT03188874 -
Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)
|
||
| Completed |
NCT00071006 -
AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
| Completed |
NCT04079296 -
A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)
|
Phase 1/Phase 2 | |
| Completed |
NCT04509622 -
A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)
|
Phase 3 | |
| Withdrawn |
NCT03699384 -
Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03613532 -
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
|
Phase 1 | |
| Completed |
NCT02252107 -
10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1
|
Phase 2 | |
| Terminated |
NCT02259348 -
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
|
Phase 2 | |
| Terminated |
NCT01463410 -
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
|
N/A | |
| Completed |
NCT01242774 -
Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)
|
Phase 1 | |
| Terminated |
NCT02134782 -
Yoga Fatigue Study
|
N/A | |
| Completed |
NCT01685619 -
AML-MDS Novel Prognostic Tests Clinical Study
|
||
| Completed |
NCT03625505 -
A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 | |
| Active, not recruiting |
NCT04266795 -
A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy
|
Phase 2 |